Home Webinars Upcoming Webinars

Upcoming Webinars

RedShiftBio webinar lead image

Exploring Novel Vaccine Characterization Methodologies

In this GEN webinar, we will discuss some typical workflows used to characterize the properties of vaccines, looking at properties such as particle size, surface charge, aggregation, and protein secondary structure.
Terumo webinar banner

Data-Driven Insights on Cell Therapy Fill and Finish Processes

In this GEN webinar, we will hear from a team of scientists who will discuss the parameters for the fill/finish and cryopreservation steps of a cell therapy manufacturing process. We will also look at data from a typical manual fill and finish process compared to data from an automated process using the Finia® Fill and Finish System.
DNA and genome editing

CRISPR-Based In Vivo Genome Editing and Base Editing

In TOMORROW's webinar, Dr. Wen Xue will present a modular delivery strategy for homology-directed repair by combining lipid nanoparticle delivery of Cas9 mRNA with adeno-associated viruses (AAV) encoding a sgRNA and a repair template.
lab equipment

Streamlining High-Throughput Impurity Analysis in Process Development

REGISTER NOW Broadcast Date: June 4, 2020 Time: 8:00 am PT, 11:00 am ET, 17:00 CET In the biopharma industry, there currently is a need to increase...
Antibody, illustration

DNA as Medicine: Encoding Cancer Therapeutic Antibodies

In this GEN webinar, sponsored by Sartorius, we will hear from two members of the clinical development and discovery research teams at Inovio. We will learn about the novel DNA-encoded monoclonal antibody (dMab™) technology and how it is being employed for cancer therapies. Additionally, our presenters will describe some current pre-clinical work using DNA-encoded immune cell engagers (DICE).
Embryonic stem cells

Looking toward the Future of Cell & Gene Therapies

In this GEN webinar, sponsored by PerkinElmer, our expert speakers, who are leading investigators in the field of cell and gene therapy, will discuss emerging gene-edited and engineered cell therapies for cancer, as well as the next generation of AAV vectors for human gene therapy.

Recently Featured

Scroll Up